---
schema_version: "secwatch.filing_event.v1"
accession: "0001232524-24-000084"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:21:35.249923+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Jazz Q3 revenue tops $1.05B, raises EPS guidance, affirms 2024 revenue outlook at $4.0-4.1B

## Summary
- Q3 2024 record revenue >$1.05B; key growth drivers (Xywav, Epidiolex, Rylaze) up 14% YoY.
- Total 2024 revenue guidance reaffirmed at $4.0-4.1B; oncology revenue guidance lowered to $1.08-1.13B.
- GAAP EPS guidance raised to $6.70-8.50; non-GAAP EPS guidance raised to $19.50-20.60.
- Xywav added ~400 net patients in Q3; strong sleep performance continues.
- Zanidatamab PDUFA Nov 29 for 2L BTC; sNDA for Zepzelca in 1L ES-SCLC planned 1H25.

## SEC filing metadata
- accession: 0001232524-24-000084
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000123252424000084/0001232524-24-000084-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000123252424000084/jazz-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001232524-24-000084
- JSON: https://secwatch.observer/filing/0001232524-24-000084.json
- Plain text: https://secwatch.observer/filing/0001232524-24-000084.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.